Pharmaceutical Executive: September 2025

View the Pharmaceutical Executive September 2025 issue in an interactive format.

Coverage highlights from the September issue of Pharmaceutical Executive offer another example of the accelerated convergence—and future hope—of AI and healthcare.

The key steps for pharma in pivoting from proof-of-concept experimenting to enterprise-scale value.

With healthcare at a key crossroads of policy, technology, and science, Sanofi CEO Paul Hudson shares the Big Pharma’s formula for navigating the new age of innovation, where running from risk is not an option.

As drugmakers navigate an increasingly complex terrain of scientific and digital influence, the ability to accurately identify and understand both key and digital opinion leaders is vital for effective engagement.

Outlining the key touchpoints for embracing change and opportunity in the “messy, tough—and fun” R&D-to-commercial transition journey.

Useful tips and parallels for staying in the game following a complete response letter.

Ways biopharma organizations and media brands can leverage coverage opportunities to help achieve respective audience goals and missions.

The quest to align cost with care, enhance data visibility, and shed the dependence on outdated revenue streams.

Can deeper data from specialty pharmacy providers bolster both patient outcomes and financial returns?

An examination of proactive preparedness and readiness review for future enrollment in the agency’s QMM program—now in the pilot stage as an effort to incentivize pharma manufacturers to achieve a more mature state of quality culture.

In today’s environment, aligning the Target Product Profile with the appropriate Value Evidence Archetype is not just good practice, it is a strategic imperative.